Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Abstract Background In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients with relapsed/refractory chronic lymph...

Full description

Bibliographic Details
Main Authors: Marco Montillo, Árpád Illés, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklós Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anna Schuh, Herbert Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Health and Quality of Life Outcomes
Subjects:
Idelalisib
Relapsed/refractory CLL
Patient-related outcomes
Health-related quality of life
Randomized phase 3 study
Online Access:http://link.springer.com/article/10.1186/s12955-019-1232-8

Internet

http://link.springer.com/article/10.1186/s12955-019-1232-8

Similar Items